Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
about
Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesisThe Promise of Preventive Cancer VaccinesAn integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological preventionp130Cas/Cyclooxygenase-2 axis in the control of mesenchymal plasticity of breast cancer cells.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.Oncoantigens for an immune prevention of cancer.Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues.Antitumor immunization of mothers delays tumor development in cancer-prone offspring.Intradermal DNA Electroporation Induces Cellular and Humoral Immune Response and Confers Protection against HER2/neu Tumor.Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.The promise of genetically engineered mice for cancer prevention studies.Inflammation and breast cancer. Inflammatory component of mammary carcinogenesis in ErbB2 transgenic mice.Bovine herpesvirus 4-based vector delivering a hybrid rat/human HER-2 oncoantigen efficiently protects mice from autochthonous Her-2(+) mammary cancerTumor-associated antigens and biomarkers in cancer and immune therapy.A plant-expressed conjugate vaccine breaks CD4(+) tolerance and induces potent immunity against metastatic Her2(+) breast cancer.Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stromaPhosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development.ErbB2 transgenic mice: a tool for investigation of the immune prevention and treatment of mammary carcinomas.Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors.Preclinical vaccines against mammary carcinoma.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy.Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas.A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.2011: the immune hallmarks of cancer.Planning a Bayesian early-phase phase I/II study for human vaccines in HER2 carcinomas.The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, ItalyOncoantigens as anti-tumor vaccination targets: the chance of a lucky strike?
P2860
Q24323685-C6EE1598-0D96-4D8B-9DA3-82FE56770E97Q26783742-90FB0A48-E1EA-481F-990C-6EEFF34BB0E1Q33229377-3943DB55-C0CE-471E-A496-694F4BBAD51CQ33739297-04D42CD2-5691-463B-B380-7045180E2521Q33786788-3B6156B9-9CD2-4741-A3B8-38C86A892196Q35083847-85E6533B-A540-41D4-96B7-F79468207B31Q35232253-F5726AD7-DD20-4B46-B08A-3013DCB3A84AQ35574950-21A8B01D-87F4-4976-A290-4CAA88B6237AQ35799346-C7506847-1129-4E35-8CBE-7D8A1DB351B8Q35890518-76B1CDBC-4912-4597-B4B2-7645964CB370Q36007167-A82777DD-C36C-4C3C-8BB4-F396BB8E2094Q36058466-56CB1953-43C4-48E6-82F0-FEFAF0FF71CFQ36393263-A36D721F-EB50-4CCE-B65C-403DFE3AA19CQ36821263-F08388E9-9C10-4AE5-BF00-37408D55818FQ36844959-BD7E4D6B-1177-4F15-8A4E-A0A30B80E358Q37078963-44A817D1-C57E-4DA4-BEC4-BF8CA453B856Q37106218-F42D8C9C-F21B-4EF9-AFD3-D0A447A69619Q37223903-EA566A07-39BF-40EB-9E6B-C99CD69D09D3Q37252893-5F020D0A-79B2-42D6-A983-A384E0DD21ABQ37289084-679BC63A-CCFC-4E4C-B9F5-F7F4D4A94972Q37412304-ECBC04FD-2CEA-4CC4-95F7-7336FC4605C7Q38160252-01B74516-BCEB-4189-867A-E75F23A02F67Q38649517-B1DDC03F-022E-4A50-9B8B-6BD30FFFD822Q39642376-0C2B4773-E657-4A7B-987C-2132BFDC7943Q39776358-91B76A41-3E84-431F-99A1-02F35D51A407Q40375544-5209DF3D-A9B8-4452-B1E7-CC6E6B1F4CBCQ40423857-1F1DC60A-B9B7-40F9-95A3-C79297E1C7E0Q42217850-B08908AD-2347-4F15-A908-1E9D867DA5F5Q46700211-390C0E35-F0EE-4DE7-9339-06493F7844DDQ57580742-FFCB61F4-3533-456E-96C7-CD070BE3EC53Q57692977-BC1552C7-751E-423A-A9B0-79BC5AAE4996
P2860
Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions
description
2004 nî lūn-bûn
@nan
2004 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի մարտին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@ast
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@en
type
label
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@ast
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@en
prefLabel
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@ast
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@en
P2093
P2860
P50
P356
P1476
Concordant morphologic and gen ...... ER-2/neu preneoplastic lesions
@en
P2093
Carla De Giovanni
Elena Quaglino
Federica Cavallo
Guido Forni
Michela Spadaro
Piero Musiani
Stefania Crispi
Stefania Lanzardo
P2860
P304
P356
10.1172/JCI19850
P407
P577
2004-03-01T00:00:00Z